Labiotech.eu

Inside Labiotech 19 May 2022

Meet the Future Makers of Labiotech

Following our recent acquisition by Inova, our team is expanding! We’re very excited to welcome three new hires to join our international team: Jim, former Editor at DairyReporter, is joining us as Editor-in-Chief. As a music composer, photographer, and podcaster, he is looking to bring in loads of creative energy and explore fun ways to […]

May 19, 2022 - 8 minutesmins - By Yi-Jen Chang

News and Trends 17 May 2022

US Giant Apollo Bags Billion-Euro Partnership with Sofinnova

As biotech investment slows following a record-breaking year, the Paris-based Sofinnova Partners has landed a €1B collaboration deal with the US investment heavyweight Apollo to nurture life sciences companies. Cementing the trend for transatlantic deals between biotech investors, the US asset manager Apollo has entered into a billion-Euro partnership with the European venture capitalist (VC) […]

May 17, 2022 - 3 minutesmins - By Anita Chakraverty

News and Trends 16 May 2022

Valneva’s Covid-19 Vaccine Contract in Dire Straits as EU Approval Lags

The stock price of the French Covid-19 vaccine maker Valneva has been knocked down by 20% as the company faces losing a supply contract with the European Commission. Despite receiving a glowing marketing authorization from the UK’s drug regulator in April this year, Valneva is struggling to gain traction with its Covid-19 vaccine in the […]

May 16, 2022 - 3 minutesmins - By Jonathan Smith

Opinion 16 May 2022

CRISPR Can Help The Switch To Sustainable Cosmetics

The cosmetics industry is looking for greener ingredients as consumers demand more sustainable products. According to Jon Kratochvil at ERS Genomics, which licenses out patents belonging to the gene editing pioneers Emmanuelle Charpentier and Jennifer Doudna, CRISPR-Cas9 could one day meet the demand for alternatives. The global cosmetics industry is worth more than €480B ($500B), […]

May 16, 2022 - 5 minutesmins - By External Contributor

News and Trends 13 May 2022

Domain Therapeutics Bags €39M to Block GPCRs in Cancer Immunotherapy

Domain Therapeutics, a biopharmaceutical company in France and Canada developing cancer immunotherapies targeting G protein-coupled receptors (GPCRs), has closed a €39M ($42M) Series A financing round to move its lead candidate to clinical trials. The approval of the first immune checkpoint inhibitor treatments in 2014 proved a gamechanger for cancer immunotherapy as they prevented tumors […]

May 13, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 12 May 2022

The Top European Biotech Investments in April 2022

Private biotech investments in Europe were on a steady decline in April 2022 as biotech public markets continued to disappoint. The top funding rounds were dominated by UK and Swiss firms targeting genetic diseases and cancer. April 2022 provided no relief for the European biotech industry as public stock markets remain anemic. Though flush with […]

May 12, 2022 - 4 minutesmins - By Jonathan Smith

News and Trends 10 May 2022

eureKARE Launches €150M Merger to Form Cell and Gene Therapy CDMO

The French startup creator eureKARE has set up a special purposes acquisition company (SPAC) with the ambition to merge multiple European contract development and manufacturing organizations into a heavyweight serving developers of gene therapies, protein drugs, and microbiome therapeutics. Over the last few years, record levels of funding have flowed into the biotech industry, particularly […]

May 10, 2022 - 4 minutesmins - By Jonathan Smith

In Depth 9 May 2022

Exosome Therapy: Borrowing from Nature’s Toolbox

In just a few years, exosomes have started gaining recognition as a solution to deliver treatments safely and effectively, and as a new approach to regenerative medicine. For hundreds of millions of years, multicellular organisms have faced many of the same challenges that biotechnology is grappling with today: how best to shuttle biomolecules to and […]

May 9, 2022 - 11 minutesmins - By Farhan Mitha

News and Trends 6 May 2022

Melt&Marble Gains €5M to Brew Fat Alternatives Using Engineered Yeast

Tapping into the increasingly sophisticated market for meat alternatives, the Swedish synthetic biology startup Melt&Marble has raised €5M in seed financing to fund the development of a fermented fat ingredient that mimics the complex properties of beef fat. Companies are racing to enhance the flavor, melt, and mouthfeel of meat alternative products such as plant-based […]

May 6, 2022 - 4 minutesmins - By Anita Chakraverty

News and Trends 5 May 2022

Amphista Lands Megadeals to Smash Cancer using Protein Degradation

As big pharma companies flock to drugs that destroy harmful proteins, the UK protein degradation specialist Amphista Therapeutics has bagged two landmark collaboration deals with the heavyweights Bristol Myers Squibb and Merck. Big pharma companies are piling onto biotechs developing drugs that can cause the destruction of target proteins in the cell — a field […]

May 5, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 3 May 2022

Tubulis Rides Investment Wave in ADCs with €60M Series B

The German firm Tubulis has raised a €60M Series B round to advance cancer drugs called antibody-drug conjugates (ADCs) to clinical trials. This takes place as the ADC space is heating up with rapid approvals and investment deals. ADCs are the product of attempts to make more selective, safer versions of traditional chemotherapy. They consist […]

May 3, 2022 - 3 minutesmins - By Jonathan Smith

stephanie bewick destiny pharma chief business officer

Expert Advice 2 May 2022

Chief Business Officers: Shedding Light on Biotech’s Dealmakers

In addition to helping patients, biotech companies need to focus on the commercial potential of their work. Stephanie Bewick at Destiny Pharma outlines her experiences of how a Chief Business Officer maximizes their company’s commercial appeal and lands deals in the biotech industry. Stephanie Bewick began her career as an academic researcher before spending more […]

May 2, 2022 - 5 minutesmins - By Victor Kotsev

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Meet the Future Makers of Labiotech

US Giant Apollo Bags Billion-Euro Partnership with Sofinnova

Valneva’s Covid-19 Vaccine Contract in Dire Straits as EU Approval Lags

CRISPR Can Help The Switch To Sustainable Cosmetics

Domain Therapeutics Bags €39M to Block GPCRs in Cancer Immunotherapy

The Top European Biotech Investments in April 2022

eureKARE Launches €150M Merger to Form Cell and Gene Therapy CDMO

Exosome Therapy: Borrowing from Nature’s Toolbox

Melt&Marble Gains €5M to Brew Fat Alternatives Using Engineered Yeast

Amphista Lands Megadeals to Smash Cancer using Protein Degradation

Tubulis Rides Investment Wave in ADCs with €60M Series B

Chief Business Officers: Shedding Light on Biotech’s Dealmakers

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!